Biotech | April 08, 2022
CDSCO approves Phase II/III trial of Akston Bio’s Covid vaccine candidate in India
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
BioFluidica LiquidScan harnesses the power of microfluidics
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Subscribe To Our Newsletter & Stay Updated
